Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Taipei Exchange - Delayed Quote TWD

Excelsior Biopharma Inc. (6496.TWO)

Compare
28.45
+0.45
+(1.61%)
At close: April 2 at 1:30:27 PM GMT+8
Loading Chart for 6496.TWO
  • Previous Close 28.00
  • Open 28.15
  • Bid --
  • Ask --
  • Day's Range 28.15 - 28.45
  • 52 Week Range 26.50 - 40.15
  • Volume 3,541
  • Avg. Volume 33,145
  • Market Cap (intraday) 1.33B
  • Beta (5Y Monthly) 0.09
  • PE Ratio (TTM) --
  • EPS (TTM) -2.14
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jul 13, 2021
  • 1y Target Est --

Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers prescription drugs, over-the-counter drugs, medical devices, healthcare food products, medical supplies, and other products. The company provides its products for the therapeutic areas, such as pediatrics, gastroenterology, neurology, cardiology, dermatology, medical toxicology, dentistry, obstetrics, oncology, hematology, and otorhinolaryngology, as well as infectious diseases. It also offers test kits under the Actim name to detect influenza virus, fecal occult blood, acute pancreatitis, preterm or full-week delivery, and early water breaking. In addition, the company provides toothpaste, and mouth wash and gel products under the Oral7 name; and food and medical beauty maintenance products. Further, it imports and exports active pharmaceutical ingredients; and engages in the research of technologies, and pharmaceutical technologies transfer and cooperative development and improvement activities. The company was formerly known as Excelsior Enterprise Co., Ltd. and changed its name to Excelsior Biopharma Inc. in June 2003. Excelsior Biopharma Inc. was incorporated in 1988 and is headquartered in Taipei, Taiwan.

www.excelsiorgroup.com.tw

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 6496.TWO

View More

Performance Overview: 6496.TWO

Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

6496.TWO
5.01%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
7.54%

1-Year Return

6496.TWO
1.97%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
4.06%

3-Year Return

6496.TWO
2.34%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
20.84%

5-Year Return

6496.TWO
21.66%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
120.40%

Compare To: 6496.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 6496.TWO

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    1.33B

  • Enterprise Value

    1.52B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.54

  • Price/Book (mrq)

    1.34

  • Enterprise Value/Revenue

    1.76

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -11.45%

  • Return on Assets (ttm)

    -3.21%

  • Return on Equity (ttm)

    -9.42%

  • Revenue (ttm)

    861.91M

  • Net Income Avi to Common (ttm)

    -98.7M

  • Diluted EPS (ttm)

    -2.14

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    251.52M

  • Total Debt/Equity (mrq)

    41.41%

  • Levered Free Cash Flow (ttm)

    -311.04M

Research Analysis: 6496.TWO

View More

Company Insights: 6496.TWO

Research Reports: 6496.TWO

View More

People Also Watch